Radiopharmaceutical R&D

Radiopharmaceutical R&D

The operating principle of radiopharmaceuticals is based on the use of a molecular « taxi » to deliver a controlled dose of radioactivity specifically to targeted diseased tissues (usually cancer cells) in order to, depending on the type of radionuclide used, either visualize (diagnosis) or cure (therapy) the tissues. Radiopharmaceuticals are generally composed of a biovector (antibody, peptide, etc.) responsible for routing the radionuclide to the targeted tissues. The bifunctional chelator firmly grips the radionuclide and ensures a strong bond with the biovector.

design of a radiopharmaceutical
EasyChelators offers its efficient and patented bifunctional chelating agents as well as its unique network of professionals to recommend the best ones to develop new radiopharmaceuticals for positron emission tomography (PET). Our strength is our ability to advice on every aspect of this type of project from ligands design and coordination chemistry to radiolabelling, in vitro and in vivo studies, PET imaging, preclinical and early clinical studies.